Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma
- PMID: 33902495
- PMCID: PMC8073913
- DOI: 10.1186/s12885-021-08104-z
Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma
Abstract
Backgroud: In our current work, we aimed to investigate the expressions of glypican (GPC) family genes at the mRNA level and assess their prognostic significances in patients with hepatocellular carcinoma (HCC).
Methods: The pathological roles of GPC family genes were examined using bioinformatics analysis. The diagnostic values of GPC genes were explored with the Gene Expression Profiling Interactive Analysis. Moreover, the mRNA expression and prognostic values of GPC genes were assessed via the KM plotter database.
Results: Our data showed that the expression of GPC-3 was dramatically increased in the liver tumor tissue. Moreover, the expressions of the other five GPC family members were not significantly different between the tumor and normal liver tissues (P > 0.05). Furthermore, the up-regulation of GPC-1 at the mRNA level was dramatically correlated to the reduced overall survival (OS) for all HCC patients (hazard ratio = 2.03, 95% confidence intervals =1.44-2.87, P = 4.1e-05) compared with its low-expression group. Besides, the prognosis of the Caucasians was related to most GPC family genes, while the prognosis of the Asian race was only related to the expression of GPC-2. Besides, for pathological factors, including stage, grade, AJCC, and vascular invasion, the higher the pathological grade and vascular invasiveness, the lower the expression levels of GPC family genes (P < 0.05). Finally, the expression levels of GPC-1, 2, and 3 in the hepatitis group were related to the poor prognosis of HCC in the risk factor (alcohol consumption and hepatitis) subgroup (P < 0.05).
Conclusions: Our findings indicated that GPC-3 was dysregulated in HCC compared with paracancerous tissues. The expression of GPC-1 could be used as a potent predictive index for the general prognosis of HCC. The pathology, patients, and risk factors might affect the prognostic value of GPC family genes in HCC.
Keywords: Bioinformatics analysis; Diagnosis; Glypicans; HCC; Prognosis.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures









Similar articles
-
Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma.Hepatobiliary Pancreat Dis Int. 2013 Apr;12(2):171-9. doi: 10.1016/s1499-3872(13)60028-4. Hepatobiliary Pancreat Dis Int. 2013. PMID: 23558072
-
Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma.Hepatobiliary Pancreat Dis Int. 2015 Aug;14(4):361-6. doi: 10.1016/s1499-3872(15)60396-4. Hepatobiliary Pancreat Dis Int. 2015. PMID: 26256079 Review.
-
Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin.Ann Surg Oncol. 2012 Jul;19 Suppl 3:S455-63. doi: 10.1245/s10434-011-1946-2. Epub 2011 Aug 6. Ann Surg Oncol. 2012. PMID: 21822558
-
Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma.Hepatobiliary Pancreat Dis Int. 2011 Jun;10(3):289-94. doi: 10.1016/s1499-3872(11)60048-9. Hepatobiliary Pancreat Dis Int. 2011. PMID: 21669573
-
Down-regulating glypican-3 expression: molecular-targeted therapy for hepatocellular carcinoma.Mini Rev Med Chem. 2014;14(14):1183-93. doi: 10.2174/1389557515666150101105135. Mini Rev Med Chem. 2014. PMID: 25553423 Review.
Cited by
-
Development and validation of a copper-related gene prognostic signature in hepatocellular carcinoma.Front Cell Dev Biol. 2023 Jul 18;11:1157841. doi: 10.3389/fcell.2023.1157841. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37534104 Free PMC article.
-
Heparan sulfate chains in hepatocellular carcinoma.Gastroenterol Rep (Oxf). 2025 Mar 14;13:goaf023. doi: 10.1093/gastro/goaf023. eCollection 2025. Gastroenterol Rep (Oxf). 2025. PMID: 40093586 Free PMC article. Review.
-
Glypican-3 Differentiates Intraductal Carcinoma and Paget's Disease from Other Types of Breast Cancer.Medicina (Kaunas). 2022 Dec 30;59(1):86. doi: 10.3390/medicina59010086. Medicina (Kaunas). 2022. PMID: 36676710 Free PMC article.
-
Pan-cancer analysis and the oncogenic role of Glypican 1 in hepatocellular carcinoma.Sci Rep. 2024 Jul 9;14(1):15870. doi: 10.1038/s41598-024-66838-9. Sci Rep. 2024. PMID: 38982153 Free PMC article.
-
The Prognostic Model Based on Tumor Cell Evolution Trajectory Reveals a Different Risk Group of Hepatocellular Carcinoma.Front Cell Dev Biol. 2021 Sep 29;9:737723. doi: 10.3389/fcell.2021.737723. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34660596 Free PMC article.
References
MeSH terms
Substances
Grants and funding
- SZSM201812055/Sanming Project of Medicine in Shenzhen
- 81800489, 81560535, 81072321, 30760243, 30460143 and 30560133/National Natural Science Foundation of China
- A2020629/Medical Scientific Research Foundation of Guangdong Province
- SZXK035/Shenzhen Key Medical Discipline Construction Fund
- SZXK035/Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties
LinkOut - more resources
Full Text Sources
Medical